List of Alkindi Sprinkle drug patents

Alkindi Sprinkle is owned by Eton.

Alkindi Sprinkle contains Hydrocortisone.

Alkindi Sprinkle has a total of 3 drug patents out of which 0 drug patents have expired.

Alkindi Sprinkle was authorised for market use on 29 September, 2020.

Alkindi Sprinkle is available in granule;oral dosage forms.

Alkindi Sprinkle can be used as treatment of adrenal insufficiency.

The generics of Alkindi Sprinkle are possible to be released after 12 May, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717740 ETON Treatment of adrenal insufficiency
Nov, 2032

(9 years from now)

US9675559 ETON Treatment of adrenal insufficiency
Jan, 2033

(9 years from now)

US9649280 ETON Composition comprising hydrocortisone
May, 2034

(11 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic